A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease.


Nine outpatients meeting research criteria for probable Alzheimer's disease who had psychosis or behavioral disturbance participated in a single-blind, placebo-controlled pilot study. Oral haloperidol in doses of 1 to 5 mg daily improved target symptoms, confirmed by double-blind ratings of videotaped interviews. Patients could not be maintained on more… (More)


  • Presentations referencing similar topics